Using a genetic mouse model and cultured cell lines, the common A118G SNP in the human MOPR gene has been shown to reduce the N-glycosylation and protein stability of the MOPR, which may account for the reduction of MOPR expression in certain brain regions. These findings may shed lights on the molecular mechanisms of the decreased clinical opioid potency in G118 allele carriers.
